KALARIS THERAPEUTICS INC (KLRS) Stock News
NASDAQ:KLRS - Nasdaq - US4829291065 - Common Stock - Currency: USD
KLRS Latest News, Press Relases and Analysis
All
Press Releases
13 days ago - Kalaris Therapeutics, Inc.
Kalaris to Participate at Stifel Ophthalmology Forum
PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company...
22 days ago - Kalaris Therapeutics, Inc.
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights
Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and...
2 months ago - Kalaris Therapeutics, Inc.
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee
Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth...
3 months ago - Kalaris Therapeutics, Inc.
Kalaris Announces Closing of Merger with AlloVir
Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF...